Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Haemonetics (HAE) Up 14.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) New Products Aid, Plasma Sales Remain Tepid
by Zacks Equity Research
Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.
Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Haemonetics (HAE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics (HAE) Up 18.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics (HAE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 12.20% and 1.35%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Haemonetics Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.
Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply
by Zacks Equity Research
Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.
Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.
What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.
What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
OPKO Health (OPK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.
Why Earnings Season Could Be Great for Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.